Stockscreener 앱 받기
0.6552
3.15%
-0.0213
시간 외 거래:
.65
-0.0052
-0.79%
전일 마감가:
$0.6765
열려 있는:
$0.6198
하루 거래량:
427.34K
Relative Volume:
1.61
시가총액:
$1.18M
수익:
-
순이익/손실:
$-3.86M
주가수익비율:
-0.027
EPS:
-24.3033
순현금흐름:
$-4.78M
1주 성능:
-20.94%
1개월 성능:
-47.16%
6개월 성능:
-98.62%
1년 성능:
-98.59%
1일 변동 폭
$0.602
$0.71
1주일 범위
$0.5949
$0.8813
52주 변동 폭
$0.5949
$52.40
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.6552 | 1.21M | 0 | -3.86M | -4.78M | -24.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Clearmind Medicine Inc 주식(CMND)의 최신 뉴스
Clearmind Medicine Inc. Advances CMND-100 Clinical Trial for Alcohol Use Disorder with Successful Cohort Treatment - Quiver Quantitative
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder - Weekly Voice
No serious adverse events as Yale, Johns Hopkins test AUD drug - Stock Titan
Clearmind Medicine regains compliance with NASDAQ minimum bid price rule - MSN
Clearmind Medicine secures six patents in Hong Kong By Investing.com - Investing.com South Africa
Aug Patterns: How do insiders feel about Clearmind Medicine Inc - baoquankhu1.vn
Clearmind Medicine secures six patents in Hong Kong - Investing.com
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies - The Manila Times
Clearmind Medicine Inc. Announces Publication of Six Patents in Hong Kong for Novel Psychedelic Combination Therapies - Quiver Quantitative
SciSparc’s NeuroThera-Backed Collaboration Spurs New Depression Therapy Patent Filing - TipRanks
SciSparc discloses patent application for depression yherapy - TipRanks
NeuroThera, Clearmind Advance Non-Hallucinogenic Depression Therapy With New Patent Filing - TipRanks
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Bitget
Non-hallucinogenic depression combo MEAI-PEA seeks Hong Kong patent - Stock Titan
NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - TheNewswire
NeuroThera LabsClearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Yahoo Finance
Clearmind advances enrollment in alcohol disorder drug trial By Investing.com - Investing.com Nigeria
Clearmind files patent for obesity, liver disease treatment combo - Investing.com Nigeria
Clearmind files Hong Kong patent for depression treatment combo - Investing.com India
Clearmind files Hong Kong patent for depression treatment combo By Investing.com - Investing.com Australia
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy - Bitget
Clearmind Medicine Inc. Files Patent for Innovative Non-Hallucinogenic Therapy Combining MEAI and PEA to Address Major Depressive Disorder - Quiver Quantitative
Clearmind Medicine (NASDAQ: CMND) files Hong Kong patent for MEAI-PEA depression therapy - Stock Titan
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
SciSparc Ltd. Advances Collaboration with NeuroThera Labs Inc. and Clearmind Medicine Inc. for Novel Combination Therapy Targeting Obesity and MASLD. - Quiver Quantitative
Clearmind advances enrollment in alcohol disorder drug trial - Investing.com India
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results - Bitget
NeuroThera and Clearmind Advance Patent for Obesity and Liver Disease Therapy - TipRanks
Clearmind Medicine Inc. Advances Enrollment for Third Cohort in Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Non-hallucinogenic AUD drug CMND-100 moves into third trial cohort - Stock Titan
NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - TheNewswire
NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Yahoo Finance
Clearmind files patent for obesity, liver disease treatment combo By Investing.com - Investing.com Canada
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
Clearmind gets safety board approval to continue AUD trial - Investing.com Nigeria
Clearmind gets safety board approval to continue AUD trial By Investing.com - Investing.com Canada
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval - Bitget
Clearmind (Nasdaq: CMND) moves CMND-100 alcohol-use trial into higher-dose stage - Stock Titan
Clearmind Medicine IncDSMB approves continuation of Phase I/IIa CMND-100 trial in AUD - marketscreener.com
Alcohol use disorder drug from Clearmind moves to higher-dose testing - Stock Titan
CMND Earnings History & Surprises | EPS & Revenue Results | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
CMND Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Clearmind Medicine Inc (CMND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):